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Highlights:  36 
 Blood stream infection (BSI) remains an important complication of BMT 37 
 Freedom from BSI was associated with superior overall survival at 2 years 38 
 This effect was most pronounced in older patients receiving RIC allografts 39 
 Pre-engraftment BSI was associated with dysregulation of IL-6 and IL-8 40 
 41 
 42 
Abstract 43 
The key complications of allogeneic bone marrow transplant (BMT) remain graft-versus-host 44 
disease (GVHD) and opportunistic infection. We have analyzed the blood stream infections 45 
(BSI) occurring between day -7 and day 100 in a cohort of 184 adult patients undergoing 46 
allogeneic BMT in our center. 167 of the 184 patients (91%) had blood cultures collected, 47 
and 69 (38%) patients had a confirmed BSI. Enterobacteriaceae, Pseudomonas aeruginosa, 48 
Enterococcus spp. and viridans Streptococcus spp. were the most commonly isolated 49 
organisms. Gender, conditioning (myeloablative vs. reduced intensity) and donor type 50 
(sibling vs. unrelated) did not differ significantly between those with and without confirmed 51 
BSI. Elevated temperature (>38C) at the time of culture collection was associated with an 52 
almost 2-fold increased likelihood of returning a positive blood culture. The absence of a BSI 53 
was associated with a significant improvement in overall survival at 2 years, due to a 54 
significant reduction in non-relapse mortality predominantly unrelated to the primary BSI. 55 
The presence of a BSI prior to engraftment was associated with the dysregulation of IL-6 and 56 
IL-8. Our findings suggest that BSI early after BMT defines a group of high-risk patients 57 
with enhanced cytokine dysregulation and poor transplant outcome.  58 
 59 
 60 
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Introduction 62 
 63 
Allogeneic bone marrow transplantation (BMT) is predominantly performed as curative 64 
therapy for high risk hematological malignancies. Graft-versus-host disease (GVHD) and 65 
opportunistic infection remain major limitations to successful outcomes. Fevers in 66 
conjunction with blood stream infections (BSI) are common in the early period after BMT
1-3
 67 
and blood cultures (BC) followed by immediate broad-spectrum empiric antimicrobial 68 
therapy remains the standard of care. The reported incidence of BSI following BMT is 12 – 69 
53%,
4, 5
 with the majority of infections occurring within the first 100 days.
6, 7
  70 
 71 
The epidemiology and resistance patterns of BSI vary significantly between centers. Gram-72 
positive bacteremias are predominantly caused by either coagulase-negative staphylococci 73 
(CoNS) or Enterococcus spp.
4-6, 8, 9
 Gram-negative organisms are isolated in 21 – 50% of BSI 74 
in the BMT setting.
4-6, 8, 9
 The most common gram-negative organisms are Escherichia coli, 75 
Klebsiella pneumoniae and Pseudomonas aeruginosa.
4, 6-12
 Fluoroquinolone resistant gram-76 
negative bacteria are of highest prevalence in centers with high rates of anti-bacterial 77 
prophylaxis with these agents (50 – 74%).9, 12 Fungemia is reported in 0.8 – 10% of BSI, and 78 
less than 5% of BSI in cohorts where systemic anti-fungal prophylaxis is used.
4, 6, 8, 9, 12
 79 
Established risk factors for BSI after BMT include older age,
10
 use of unrelated donors,
13
 80 
donor-recipient HLA mismatches, myeloablative conditioning,
13, 14
 longer duration of 81 
neutropenia,
5, 10
 and severe acute GVHD.
11
 BSI has been associated with decreased survival 82 
in the first 6 months after BMT, particularly when multi-resistant organisms are isolated.
5, 10, 
83 
12-15
  84 
 85 
Acute GVHD is characterized by an early cytokine storm dominated by IL-6, TNF and 86 
IFN.16-18 These cytokines are produced by both donor and recipient cells, and therapies that 87 
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inhibit cytokine generation from effector donor T cells are a key component of GVHD 88 
prophylaxis and treatment.
19
 It is clear that damage and pathogen-associated molecular 89 
patterns (DAMP/PAMPs) originating from the microbiome and migrating across a damaged 90 
gastrointestinal tract (GI tract) play an important role in promoting these cytokine responses 91 
and acute GVHD.
20,21
 To date however, this has not been attributed to intact bacteria (i.e. 92 
BSI) within the systemic circulation.  Here we report the epidemiology of BSI in this patient 93 
group in our center and examine the consequences of BSI with regard to cytokine 94 
dysregulation and transplant outcome. 95 
 96 
Materials and Methods 97 
 98 
Patients 99 
Patients underwent BMT at the Royal Brisbane and Women’s Hospital (RBWH) between 100 
2009 and 2015, with the majority of patients recruited between 2012 and 2013. Inclusion 101 
criteria for the cohort were: age 18 – 75 years, able to provide informed consent, negative for 102 
hepatitis B and C, and HIV on routine BMT workup, and not enrolled in another study. 103 
Patients underwent T-replete, peripheral blood stem cell (PBSC) allogeneic SCT and from 104 
either volunteer unrelated donors (VUD) or matched sibling donors. For unrelated donors, 105 
high-resolution sequence-based typing was performed (HLA-A, B, C, DRB1 and DQ). 106 
Conditioning was either cyclosphosphamide with total body irradiation (60 mg/kg per day for 107 
days –5 and –4, plus 12 Gy TBI over days -3 to -1; Cy TBI, myeloablative conditioning 108 
[MAC] protocol) or fludarabine and melphalan (25 mg/m
2
 fludarabine from day -7 to -3 and 109 
melphalan 120mg/m
2
 on d-2; Flu Mel, reduced intensity conditioning [RIC] protocol). 110 
Standard GVHD prophylaxis was cyclosporin (5 mg/kg per day on days –1 to +1, then 3 111 
mg/kg per day to maintain therapeutic levels with trough levels of 140–300 ng/mL) for 100 112 
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days (with weaning thereafter at clinician discretion) plus methotrexate (15 mg/m
2
 on day 1, 113 
then 10 mg/m
2
 on days 3, 6, and 11). Routine antimicrobial prophylaxis consisted of 114 
norfloxacillin (from commencement of conditioning to either neutrophil engraftment or 115 
escalation to intravenous antibiotics), trimethoprim/sulfamethoxazole, valaciclovir or 116 
acyclovir, and fluconazole. The first-line empiric antimicrobial was piperacillin-tazobactam, 117 
with the addition of vancomycin if central venous line associated sepsis was suspected. 118 
Adjustment to first-line antibiotics were made in the setting of drug allergy, colonization with 119 
resistant organisms, or known previous infection with organisms resistant to piperacillin-120 
tazobactam. 121 
 122 
Blood cultures 123 
Blood cultures were collected from each lumen of central lines, and peripherally where 124 
possible, at temperatures ≥ 38C as per unit protocol, and on physician request. Blood 125 
cultures were collected using standard clinical procedures, incubated and monitored for 126 
positivity using the BacT/Alert 3D system (bioMérieux, Marcy l’Etoile, France). Bacterial 127 
susceptibility testing was performed according to Clinical and Laboratory Standards Institute 128 
(CLSI) standards,
22
 transitioning to European Committee on Antimicrobial Susceptibility 129 
Testing (EUCAST) standards in 2012.
23
 CLSI clinical breakpoints, where available, were 130 
used for fungal susceptibility testing. Where patients had multiple consecutive episodes of 131 
BC where the same organism was isolated, the organism was included only once in the 132 
frequency and susceptibility analysis.  Organisms which are common skin contaminants, such 133 
as coagulase-negative staphylococcus (CoNS), Bacillus spp. and Cutibacterium 134 
(Propionibacterium) acnes, were only considered significant if they were isolated from all 135 
line and peripheral blood cultures collected in a single episode.
24
  136 
 137 
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 138 
 139 
Data collection and definitions 140 
Clinical data were collected from transplant protocols and retrospective review of the medical 141 
records. Microbiological data were collected from our institutional pathology database. Age, 142 
gender, BMT indication, donor type, induction protocol, day of engraftment (defined as 2 143 
consecutive days with ANC >0.5 x 10
9
/L), acute GVHD (grading by Seattle criteria
25
), date 144 
of GVHD diagnosis, and CMV reactivation (2 consecutive qPCR results of >600 copies/mL) 145 
were recorded. 146 
 147 
Time and date stamps were used to define separate episodes of BC collection and where BC 148 
were collected within 2 hours of index we considered them part of a single clinical episode. 149 
Features at the time of the episode were collected from retrospective review, including 150 
patient observations, antimicrobial therapy, total parenteral nutrition (TPN) at time of BC 151 
collection and ANC. Fever was defined as peripheral body temperature 38C and 152 
hypotension defined as systolic blood pressure <90mm Hg.
26
 153 
 154 
Cytokine analysis 155 
Cytokines measured were: IL-1, IL-6, IL-8, TNF and IFN Blood samples were collected at 156 
day -7, 0, +3, +7, +14, +21, +30, +60, +90 and +120. Serum was prepared and stored at -80
◦
C 157 
until time of analysis. Serum cytokines were analyzed using cytokine bead array (CBA; BD 158 
Biosciences, Sparks, USA), with data acquired using a BD LSR Fortessa high-throughput 159 
system (BD Biosciences, Sparks, USA). Quantification controls for each cytokine were 160 
performed for each 96-well sample plate. Some of the cytokine data for these patients has 161 
been reported previously, independently of this analysis of BSI.
27
 162 
Page 6 of 24
 6 
 163 
Statistical analysis 164 
Data were collated using Microsoft Excel. GraphPad Prism (Version 6.00, GraphPad 165 
Software, USA) was used for the generation of graphs and for statistical analysis. 166 
Contingency analyses (Fisher’s exact test) were used to measure associations. Kaplan-Meier 167 
time to event analyses were performed (Log-Rank test). Significant differences in cytokine 168 
levels in patients with and without BSI were assessed using Mann-Whitney non-parametric 169 
analyses at each time point.  170 
 171 
Ethics 172 
The observational study protocol was approved by both the QIMR Berghofer Medical 173 
Research Institute and RBWH Human Research Ethics Committees with written informed 174 
consent obtained from all patients 175 
 176 
 177 
  178 
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Results  179 
 180 
Patient characteristics and BSI frequency 181 
184 patients were enrolled in our cohort (Table 1), with the majority undergoing transplant 182 
for myelodysplastic syndrome (MDS) or acute myeloid leukemia (52%). Between day -7 and 183 
day 100, 167 patients (91%) had a clinically indicated BC collected, on 777 separate 184 
occasions. On a per-episode basis, 217 (28%) of these yielded positive results, 111 (14%) of 185 
which were for clinically significant organisms. On a per-patient basis, 69 patients in our 186 
cohort experienced a BSI. Thirty-five patients (51% of the positives) confirmed a BSI prior to 187 
neutrophil engraftment, 25 (36%) after engraftment, and 9 patients (13%) had separate BSIs 188 
proven both prior to and after engraftment. 189 
 190 
From 111 positive blood culture episodes, 93 unique organisms were associated with a BSI. 191 
Gram-negative organisms were isolated in 54 cases (58% of total). The most commonly 192 
isolated gram-negative bacteria were Pseudomonas aeruginosa (12, 22%), Klebsiella 193 
pneumoniae (9, 17%) and Escherichia coli (7, 13%). Among all gram-negative isolates 194 
recovered, 21 (38.9%) were resistant to piperacillin-tazobactam and 6 (11.1%) were resistant 195 
to meropenem. The presence of extended spectrum beta-lactamase (ESBL) was identified as 196 
the mechanism of antimicrobial resistance in 4 (7%) gram-negative isolates. Gram-positive 197 
organisms were isolated in 35 (38% of total) cases. The most common gram-positive bacteria 198 
identified were Enterococcus spp. (12 isolates, 34%) and viridans Streptococcus spp. (12 199 
isolates, 34%). Piperacillin-tazobactam resistance was observed in 13 (37%) of the gram-200 
positive isolates, associated with Enterococcus faecium (7 episodes), methicillin resistant 201 
Staphylococcus epidermidis (3 episodes), MRSA (1 episode), and viridans streptococci (2 202 
episodes). Four vanB phenotype E. faecium were detected. No vanA VRE was detected, and 203 
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no daptomycin or linezolid resistance was observed. Two fungal BSI occurred, one each with 204 
Lomentospora prolificans and Candida glabrata. Organisms isolated and their resistance 205 
patterns are described in Table 2.  206 
 207 
Characteristics of BC episodes confirming BSI 208 
Donor source (related vs. unrelated), conditioning regimen (MAC vs RIC) and recipient age 209 
had no relationship with BSI incidence (Table 3). The majority of BC were collected in 210 
febrile patients (62% of episodes; T≥38◦C) and these yielded significant organisms more 211 
frequently than afebrile episodes (17% vs 9%; OR 1.9, 95% CI 1.21 – 3.23; p = 0.0058; 212 
Table 3). The organisms isolated from febrile patients were not, however, different to those 213 
isolated from afebrile patients. Of note, in this series, neutropenia, hypotension, timing of 214 
episode (relative to engraftment) and TPN were not associated with proven BSI. Average 215 
time to engraftment was 16.5 ± 4.6 days and was not different between patients with and 216 
without BSI (p = 0.65). On a per-patient basis, CMV reactivation at any time before day 100 217 
was not associated with BSI (OR 1.38, 95% CI 0.71 – 2.65; p = 0.39). The most commonly 218 
used empiric gram-negative targeted antimicrobials were piperacillin-tazobactam (45%) and 219 
meropenem (32%). Empiric gram-positive targeting agents were used frequently, 220 
vancomycin in 50% of episodes and teicoplanin in 10 % of episodes.  221 
 222 
Patient outcomes associated with BSI 223 
We compared 2-year overall survival (OS) in patients who never experienced a BSI 224 
compared with those who did (Fig 1A). BSI-free status was associated with a significant 225 
improvement in 2 year overall survival (HR 0.59, 95% CI 0.37-0.95; p = 0.01). Ten patients 226 
died within 30 days of BSI. When these patients were excluded from the analysis, BSI-free 227 
status still conferred a significant survival benefit (HR 0.50, 95% CI: 0.28 – 0.94; p = 0.023). 228 
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This was not due to higher rates of relapse mortality in this group, but rather, attributable 229 
entirely to non-relapse mortality (NRM; Fig 1B-C). In patients with a BSI prior to their 230 
diagnosis of GVHD, no significant difference in the cumulative incidence of severe aGVHD 231 
was seen (Fig 1D), however there was significantly higher mortality attributed to aGVHD 232 
(11.6% vs 0.9%, p = 0.0019) in the patients who experienced a BSI. For patients with BSI 233 
any time before day 100, there was a trend towards a higher incidence of extensive chronic 234 
GVHD relative to those without confirmed BSI (34.7% in the BSI group vs 21.7% in the 235 
BSI-free group; p = 0.06). There was no significant difference in the relapse rate at 2 years 236 
between patients with BSI and those without (p = 0.47). 237 
 238 
When stratified by conditioning, differences in OS between BSI and BSI-free patients were 239 
maintained in patients who underwent reduced intensity (with fludarabine and melphalan) 240 
conditioning, whereas no difference was seen in the patients undergoing myeloablative (Cy 241 
TBI) conditioning (Fig 2A-B). The median age of patients undergoing MAC transplantation 242 
was 35 (range 18 – 52) compared with 59 (range 20 – 70) in the RIC patients (P<0.0001). 243 
Among those undergoing BMT after reduced intensity conditioning, the majority received 244 
transplants from VUD donors and the association between BSI and decreased overall survival 245 
was maintained for the VUD cohort, but not the recipients of sibling allografts (Fig 2C-D). It 246 
should be noted however that numbers in the latter group were small (34 patients in total).  247 
 248 
Cytokine analysis 249 
To assess cytokine dysregulation associated with BSI, we focused on patients who had a 250 
confirmed BSI before engraftment, and compared them to those who had sterile blood 251 
cultures collected (for any clinical indication). IL-6 and IL-8 were elevated at multiple time 252 
points early following transplant and were influenced by conditioning intensity and BSI (Fig 253 
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3). Other cytokines analyzed (IFN, IL-1, and TNF) were not differentially impacted by early 254 
BSI (data not shown).    255 
 256 
Discussion 257 
 258 
In this cohort study, one-third of patients experienced a confirmed BSI in the first 100 days 259 
after BMT. Gram-negative bacilli, enterococci and viridans streptococci were the most 260 
commonly isolated organisms and resistance to piperacillin-tazobactam amongst gram-261 
negative isolates was higher than previously reported in Australian cohorts
28
 due to both 262 
intrinsic and acquired resistance mechanisms. This may reflect changes in patient 263 
colonization associated with recurrent exposure to piperacillin-tazobactam during AML 264 
induction and consolidation therapy, typically the first-line agent for febrile neutropenia at 265 
our center. 266 
 267 
When we used the presence or absence of a BSI to divide the patient cohort, BSI was 268 
associated with poorer 2-year overall survival while relapse mortality (2 year) and classical 269 
severe acute GVHD (i.e. before day 100) were similar. The difference in OS is thus likely 270 
due to other transplant-related complications, including chronic GVHD and later 271 
opportunistic infection. In stratified analysis, the association remained strongest in the 272 
patients undergoing reduced intensity allografts with unrelated donors, though small numbers 273 
in the myeloablative subgroup precludes a firm conclusion that the BSI and BSI-free patients 274 
are equivalent in this setting. While age was not in itself a risk factor for proven BSI in this 275 
study, the group receiving reduced intensity allografts were significantly older than the group 276 
receiving myeloablative transplants, which is likely to impact outcome. It is also possible that 277 
this older group experienced more pre-transplant BSI (or other significant infections) than the 278 
younger patients treated with myeloablative conditioning, but due to the retrospective nature 279 
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of data collection for this study we were unable to explore this. The role of pre-transplant BSI 280 
as a risk factor should be explored in future prospective studies. It remains unclear whether a 281 
BSI reflects additional baseline risk factors not identified in this study, serving as a surrogate 282 
for high-risk patients. In contrast, it is possible that BSI itself promotes immune dysfunction 283 
and leads to downstream complications. Indeed defects in both antigen presentation and 284 
immune dysfunction have been noted in systemic cytokine release syndromes,
29
 consistent 285 
with this possibility, and now require further exploration.  286 
 287 
With larger patient numbers it is likely that early BSI would be associated with higher rates 288 
of severe aGVHD than BSI-free status, as this has been reported by others. It is also likely 289 
that severe aGVHD (particularly of the GI tract) would predispose to subsequent BSI. 
30
 290 
There were 5 patients who only experienced BSI after their diagnosis of severe, grade 3-4 291 
aGVHD, and a further four who experienced BSI both prior to and after the onset of GVHD, 292 
these small numbers prevented any assessment of the role of GVHD itself as a causal factor 293 
of BSI in this cohort.  294 
 295 
All patients included in the cytokine analysis had early fevers and exposure to broad 296 
spectrum antibiotics, and there were no differences in the empiric antibiotic choice between 297 
those who ultimately went on to have proven BSI and those who did not.  It is nevertheless 298 
possible that duration of antibiotic exposure may contribute to BMT outcome, given the 299 
mounting evidence that disruption of the microbiome after BMT is detrimental to survival.
31
 300 
However, the lack of available stool samples in this patient cohort meant that we could not 301 
assess this possibility and we suggest that this would be a valuable addition to future studies. 302 
 303 
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IL-6 and IL-8 have been implicated as causative factors in both acute GVHD and the 304 
response to sepsis. IL-8 is particularly interesting as a biomarker for the severity of septic 305 
episodes in critical illness,
32, 33
 despite some contradictory results.
34
 IL-8, also referred to as 306 
neutrophil chemotactic factor and CXCL8, is involved in neutrophil and T cell chemotaxis 307 
during inflammation, and is produced by a variety of cells and tissues, including 308 
monocyte/macrophages, neutrophils themselves and epithelial cells within the GI tract.
35, 36
 In 309 
that context, IL-8 has also been examined as a biomarker for acute GVHD, and has been 310 
reported as useful in combination with other cytokines, including IL-2, TNFR1, and 311 
hepatocyte growth factor.
37
 It is thus biologically plausible that elevated IL-8 in the early 312 
post-transplant period can contribute to downstream tissue damage and transplant-related 313 
mortality, though this has not yet been explored in mouse or clinical studies of BMT. IL-6, in 314 
contrast, has been demonstrated to have a pathogenic role in GVHD in experimental models, 315 
and more recently in the clinical setting, with favorable results demonstrated in a phase I/II 316 
study of tocilizumab for GVHD prevention.
27, 38-40
 IL-6 can be produced by most cell types, 317 
and signals via an IL-6 receptor/gp130 heterodimer, of which expression is restricted to T 318 
cells, monocytes and hepatocytes. While we have been able to associate IL-6 dysregulation 319 
with BSI in this study, a much larger study would be needed to analyze the effects of IL-6 320 
and BSI on acute GVHD in a multivariate fashion. 321 
 322 
This is the first study reporting a BSI-specific induction of these cytokines in the setting of 323 
the broader cytokine dysregulation after BMT. The contribution of BSI to cytokine 324 
dysregulation and transplant-related mortality now needs to be studied in large prospective 325 
multi-center studies, ideally in conjunction with microbiome analysis. 326 
 327 
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 468 
Figure 1: Cumulative incidence of GVHD and 2 year overall survival 469 
A) Overall survival at 2 years amongst patients with and without BSI in the period d-7 to day 470 
100. B) Non-relapse mortality (NRM) at 2 years. C) Cumulative relapse mortality, at 2 years. 471 
D) Kaplan-Meier analysis shown of severe acute GVHD in patients with and without proven 472 
BSI. n = 19 with acute GVHD in the 69 patient BSI group and n = 12 in the 115 patient BSI-473 
free group.  474 
 475 
Figure 2: Stratified OS analysis 476 
A) Kaplan-Meier analysis of OS for the myeloablative (MAC) and B) Reduced intensity 477 
conditioning (RIC) subgroups. C-D) Further stratification of OS in the reduced intensity 478 
group, by donor type.  479 
 480 
Figure 3: Cytokine analysis in patients with and without confirmed BSI 481 
A) IL-6 levels between day -7 and day 120 are shown in patients with pre-engraftment 482 
proven BSI and those who had blood cultures collected during the same window but did not 483 
return positive results. Individual data points shown, line at mean. Stratified by conditioning. 484 
B) As shown in A, IL-8 levels.  485 
 486 
 487 
 488 
  489 
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Table 1: Patient characteristics 490 
Characteristics  Observational 
cohort 
n = 184 (%) 
Age (Median +/- range) 52 (18-70) 
Female recipients 76 (41.3%) 
  
Indication for transplant   
Acute myeloid leukemia 65 (35.9%) 
Acute lymphoblastic 
leukemia 34 (18.2%) 
Myelodysplasia 31 (16.6%) 
Lymphoproliferative disorder 36 (14.4%) 
Myeloproliferative disorder 18 (11.0%) 
   
Donor source   
Sibling 63 (34.2%) 
Unrelated 121 (65.8%) 
   
Conditioning   
Cy TBI (MAC) 57 (31.0%) 
Flu Mel (RIC) 124 (67.4%) 
Other 3 (1.6%) 
 491 
 492 
 493 
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Table 2: Organisms and susceptibility associated with blood stream infection 
Organism n % Significant Resistance Phenotypes 
/Mechanisms 
n % 
GRAM-NEGATIVE 
ORGANISMS 
5
4 
100 Piperacillin-tazobactam resistant 2
1 
38.
9 
Meropenem resistant 6 11.
1 
Pseudomonas aeruginosa 1
2 
22.
2 
Piperacillin-tazobactam resistant 2 3.7 
Meropenem resistant 3 5.6 
Klebsiella pneumoniae 9 16.
7 
Piperacillin-tazobactam resistant (ESBL) 1 1.9 
Escherichia coli 7 13.
0 
Piperacillin-tazobactam resistant (ESBL) 3 5.6 
Klebsiella oxytoca 5 9.3 -   
Enterobacter spp. 5 9.3 -   
Stenotrophomonas maltophilia 3 5.6 -   
Acinetobacter sp. 2 3.7 -   
Sphingomonas paucimobilis 2 3.7 -   
Ralstonia mannitolilytica 2 3.7 -   
Aeromonas hydrophila 1 1.9 -   
Capnocytophaga sp. 1 1.9 -   
Methylobacterium sp. 1 1.9 -   
Pantoea sp.  1 1.9 -   
Pseudomonas fluorescens 1 1.9 -   
Pseudomonas putida 1 1.9 -   
Serratia marcescens 1 1.9 -   
GRAM-POSITIVE ORGANISMS 3
5 
100 Piperacillin-tazobactam resistant 1
3 
37.
4 
Streptococcus mitis group 9 25.
7 
Penicillin-resistant 2 5.7 
Enterococcus faecium 7 20.
0 
VRE vanB 4 11.
4 
Enterococcus faecalis 5 14.
3 
-   
Staphylococcus aureus 5 14.
3 
MRSA 1 2.9 
Staphylococcus epidermidis 4 11.
4 
MRSE 3 8.6 
Gemella haemolysans 1 2.9 -   
Granulicatella adiacens 1 2.9 -   
Streptococcus salivarius 1 2.9 -   
Streptococcus sanguinis 1 2.9 -   
Streptococcus gordonii 1 2.9 -   
FUNGI      
Candida glabrata complex 1  Fluconazole SDD 1  
Lomentospora prolificans 1     
ANAEROBIC ORGANISMS      
Clostridium sp. 1     
Veillonella parvula 1     
TOTAL 9     
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3 
ESBL: Extended spectrum -lactamase, MRSA: Methicillin resistant Staphylococcus aureus. 
MRSE: Methicillin resistant Staphylocccus epidermidis, VRE: Vancomycin resistant 
Enterococcus, SDD: Susceptible dose dependent. One Streptococcus mitis group isolate did 
not undergo susceptibility testing.  
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Table 3:  Risk factors for confirmed BSI  
Patient-specific risk factor OR 95% CI P value 
Donor    
Related  1   
Unrelated 0.76 0.41 – 1.41  0.42 
Conditioning regimen    
Myeloablative 1   
Reduced intensity 0.71 0.37 – 1.35 0.33 
Age    
 50 years  1   
> 50 years 0.953 0.53-1.77 >0.99 
Episode-specific risk factor    
Fever (T >38)     
No 1   
Yes 1.97 1.21 – 3.23 0.0058 
Neutropenia (ANC <0.5)    
No 1   
Yes 1.427 0.95 – 2.15 0.09 
Hypotension (<90 SBP)    
No  1   
Yes 1.32 0.39 – 4.5 0.72 
Pre-engraftment     
No 1   
Yes 1.096 0.74 – 1.65 0.68 
TPN at time of BC collect    
No 1   
Yes 0.73 0.42 – 1.29 0.35 
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